argenx SE (ARGX) 10-Year Financial Performance & Capital Metrics

ARGX •

HealthcareBiotechnologyImmunology and Inflammation Therapies

Aboutargenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.Show more

Revenue $2.19B +78.6%
EBITDA -$4M +98.7%
Net Income $833M +382.3%
EPS (Diluted) 12.78 +347.7%
Gross Margin 89.62% -0.9%
EBITDA Margin -0.19% +99.3%
Operating Margin -0.99% +97.1%
Net Margin 38.03% +258.1%
ROE 17.36% +303.3%
ROIC -0.53% +96.6%
Debt/Equity 0.01 +45.5%
Interest Coverage -9.76 +97.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 94.6%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 14.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y85.39%

5Y94.61%

3Y63.92%

TTM335.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM176.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM167.07%

ROCE

10Y Avg-20.84%

5Y Avg-16.64%

3Y Avg-13.15%

Latest-0.45%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.49M	15.47M	43.69M	24.57M	78.46M	41.24M	497.28M	410.75M	1.23B	2.19B
Revenue Growth %	64.07%	106.51%	182.33%	-43.75%	219.3%	-47.44%	1105.72%	-17.4%	198.56%	78.6%
Cost of Goods Sold+	0	0	0	0	0	0	0	29.43M	117.83M	227.29M
COGS % of Revenue	-	-	-	-	-	-	-	7.17%	9.61%	10.38%
Gross Profit+	7.49M	15.47M	43.69M	24.57M	78.46M	41.24M	497.28M	381.31M	1.11B	1.96B
Gross Margin %	100%	100%	100%	100%	100%	100%	100%	92.83%	90.39%	89.62%
Gross Profit Growth %	64.07%	106.51%	182.33%	-43.75%	219.3%	-47.44%	1105.72%	-23.32%	190.7%	77.08%
Operating Expenses+	24.55M	38M	71.2M	118.2M	277.35M	518.86M	846.02M	1.1B	1.53B	1.98B
OpEx % of Revenue	327.69%	245.55%	162.98%	481.02%	353.49%	1258.06%	170.13%	268.21%	125.05%	90.61%
Selling, General & Admin	5.38M	7.37M	14.93M	31.42M	72.15M	170.55M	305.52M	469.92M	709.54M	1.06B
SG&A % of Revenue	71.87%	47.65%	34.18%	127.88%	91.95%	413.53%	61.44%	114.41%	57.86%	48.18%
Research & Development	22.56M	33.19M	62.07M	95.64M	220.77M	370.49M	580.52M	663.37M	859.49M	983.42M
R&D % of Revenue	301.08%	214.48%	142.09%	389.21%	281.37%	898.31%	116.74%	161.5%	70.09%	44.9%
Other Operating Expenses	-3.39M	-2.56M	-5.81M	-8.86M	-15.56M	-22.18M	-40.02M	-31.63M	-35.5M	-54.16M
Operating Income+	-17.06M	-22.52M	-27.51M	-93.63M	-198.89M	-477.62M	-348.75M	-720.34M	-425.05M	-21.65M
Operating Margin %	-227.69%	-145.55%	-62.98%	-381.02%	-253.49%	-1158.06%	-70.13%	-175.37%	-34.66%	-0.99%
Operating Income Growth %	-30.6%	-32.01%	-22.15%	-240.31%	-112.43%	-140.14%	26.98%	-106.55%	40.99%	94.91%
EBITDA+	-16.85M	-22.17M	-26.99M	-93.06M	-196.47M	-473.7M	-342.88M	-616M	-313.57M	-4.13M
EBITDA Margin %	-224.83%	-143.28%	-61.78%	-378.72%	-250.4%	-1148.56%	-68.95%	-149.97%	-25.57%	-0.19%
EBITDA Growth %	-30.56%	-31.61%	-21.73%	-244.8%	-111.11%	-141.11%	27.62%	-79.65%	49.1%	98.68%
D&A (Non-Cash Add-back)	214.29K	351.27K	521.87K	563.94K	2.42M	3.92M	5.87M	104.34M	111.48M	17.53M
EBIT	-16.74M	-22.52M	-32.97M	-93.63M	-175.78M	-604.95M	-398.65M	-727.12M	-303.59M	87.64M
Net Interest Income+	83.09K	64.15K	197.95K	4.23M	8.67M	4.75M	2.39M	22.55M	92.06M	136.28M
Interest Income	83.09K	64.15K	197.95K	4.23M	8.8M	5.15M	3.48M	24.74M	92.96M	138.5M
Interest Expense	0	0	0	0	139K	403.66K	1.1M	2.19M	904K	2.22M
Other Income/Expense	320.34K	44.17K	-5.46M	18.3M	22.97M	-127.73M	-51M	-8.97M	120.55M	106.83M
Pretax Income+	-16.74M	-22.48M	-32.97M	-75.32M	-175.92M	-605.35M	-399.74M	-729.31M	-304.5M	85.18M
Pretax Margin %	-223.42%	-145.27%	-75.46%	-306.53%	-224.21%	-1467.77%	-80.39%	-177.56%	-24.83%	3.89%
Income Tax+	0	0	716.22K	908.26K	5.29M	3.1M	8.52M	-19.72M	-9.44M	-747.86M
Effective Tax Rate %	100%	100%	102.17%	101.21%	103.01%	100.51%	101.97%	97.3%	96.9%	977.98%
Net Income+	-16.74M	-22.48M	-33.68M	-76.23M	-181.21M	-608.46M	-407.63M	-709.59M	-295.05M	833.04M
Net Margin %	-223.42%	-145.27%	-77.1%	-310.22%	-230.95%	-1475.29%	-81.97%	-172.76%	-24.06%	38.03%
Net Income Growth %	-33.48%	-34.28%	-49.84%	-126.32%	-137.71%	-235.78%	33.01%	-74.08%	58.42%	382.34%
Net Income (Continuing)	-16.74M	-22.48M	-33.68M	-76.23M	-181.21M	-608.46M	-408.26M	-709.59M	-295.05M	833.04M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.06	-1.20	-1.37	-2.12	-4.69	-13.40	-7.99	-13.05	-5.16	12.78
EPS Growth %	-32.5%	-13.21%	-14.17%	-54.74%	-121.23%	-185.71%	40.37%	-63.33%	60.46%	347.67%
EPS (Basic)	-1.06	-1.19	-1.37	-2.12	-4.69	-13.40	-7.99	-13.05	-5.16	13.92
Diluted Shares Outstanding	15.73M	18.82M	24.61M	35.98M	38.62M	45.41M	51.08M	54.38M	57.17M	65.18M
Basic Shares Outstanding	15.73M	18.82M	24.61M	35.98M	38.62M	45.41M	51.08M	54.38M	57.17M	59.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.26M	107.06M	440.06M	654.82M	1.54B	2.06B	2.54B	2.77B	4.12B	4.88B
Cash & Short-Term Investments	46.28M	101.73M	431.62M	645.81M	1.5B	2B	2.34B	2.19B	3.18B	3.38B
Cash Only	38.83M	94.55M	228.98M	321.48M	372.16M	1.22B	1.33B	800.74M	2.05B	1.5B
Short-Term Investments	7.45M	7.18M	202.64M	324.33M	1.13B	779.65M	1B	1.39B	1.13B	1.88B
Accounts Receivable	719K	1.12M	845K	4.36M	36.17M	7.44M	38.22M	277.27M	499.27M	909.1M
Days Sales Outstanding	35.02	26.37	7.06	64.71	168.26	65.85	28.05	246.39	148.6	151.5
Inventory	0	0	0	0	0	25.2M	109.08M	228.35M	310.55M	407.23M
Days Inventory Outstanding	-	-	-	-	-	-	-	2.83K	961.94	653.97
Other Current Assets	637K	826.64K	3.85M	2.31M	0	0	0	0	0	0
Total Non-Current Assets+	2M	4.18M	4.92M	6.88M	67.54M	222.41M	307.3M	360.06M	418.72M	1.32B
Property, Plant & Equipment	272.23K	805.6K	811K	942.58K	9.18M	11.58M	15.84M	16.23M	22.68M	43.52M
Fixed Asset Turnover	27.52x	19.21x	53.87x	26.07x	8.55x	3.56x	31.39x	25.30x	54.08x	50.33x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7.65K	17.88K	15.6K	64.06K	45.12M	167.34M	171.68M	174.9M	125.23M	181.44M
Long-Term Investments	1.09K	1.05K	1.2K	1.14K	2.92M	6.31M	53.17M	40.48M	47.16M	49.7M
Other Non-Current Assets	1.71M	3.36M	4.1M	5.87M	10.33M	22.14M	34.42M	49.23M	126.45M	120.46M
Total Assets+	50.25M	111.24M	444.98M	661.7M	1.61B	2.28B	2.85B	3.13B	4.54B	6.2B
Asset Turnover	0.15x	0.14x	0.10x	0.04x	0.05x	0.02x	0.17x	0.13x	0.27x	0.35x
Asset Growth %	-14.12%	121.38%	300.01%	48.7%	143.35%	41.56%	25.04%	9.96%	44.93%	36.55%
Total Current Liabilities+	9.43M	34M	29.41M	45.82M	179.7M	328.49M	301.24M	302.28M	422.99M	669.92M
Accounts Payable	2.94M	4.63M	5.28M	6.87M	10.51M	206.32M	208.85M	188.72M	245.56M	342.23M
Days Payables Outstanding	-	-	-	-	-	-	-	2.34K	760.63	549.58
Short-Term Debt	0	0	0	0	2.22M	3.48M	3.51M	3.42M	4.65M	6.53M
Deferred Revenue (Current)	4.5M	37.27M	16.95M	23.21M	136.28M	46.33M	0	0	0	0
Other Current Liabilities	449.73K	329.08K	0	0	0	0	828K	22.62M	73.35M	156.95M
Current Ratio	5.12x	3.15x	14.96x	14.29x	8.58x	6.26x	8.44x	9.18x	9.75x	7.29x
Quick Ratio	5.12x	3.15x	14.96x	14.29x	8.58x	6.19x	8.08x	8.42x	9.01x	6.68x
Cash Conversion Cycle	-	-	-	-	-	-	-	737.91	349.92	255.89
Total Non-Current Liabilities+	0	10.59M	1.75M	8.01K	250.11M	276.86M	14.81M	18.29M	21.96M	34.32M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	5.1M	6.18M	7.96M	9.01M	15.35M	32.52M
Deferred Tax Liabilities	0	0	0	0	0	1.49M	6.44M	8.41M	5.16M	0
Other Non-Current Liabilities	0	10.59M	1.75M	8.01K	72K	156K	417K	870K	1.45M	1.8M
Total Liabilities	9.43M	44.59M	31.16M	45.83M	429.81M	605.36M	316.05M	320.56M	444.95M	704.24M
Total Debt+	0	0	0	0	7.32M	9.66M	11.46M	12.43M	20M	39.05M
Net Debt	-38.83M	-94.55M	-228.98M	-321.48M	-364.84M	-1.2B	-1.32B	-788.31M	-2.03B	-1.46B
Debt / Equity	-	-	-	-	0.01x	0.01x	0.00x	0.00x	0.00x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-1430.88x	-1183.22x	-318.20x	-328.47x	-470.19x	-9.76x
Total Equity+	40.76M	66.65M	413.81M	615.87M	1.18B	1.67B	2.53B	2.81B	4.1B	5.5B
Equity Growth %	-33.08%	63.54%	520.87%	48.83%	91.66%	41.82%	51.38%	11.03%	45.63%	34.19%
Book Value per Share	2.59	3.54	16.81	17.12	30.57	36.87	49.62	51.74	71.67	84.36
Total Shareholders' Equity	40.76M	66.65M	413.81M	615.87M	1.18B	1.67B	2.53B	2.81B	4.1B	5.5B
Common Stock	1.73M	2.12M	3.86M	4.12M	5.21M	5.74M	6.23M	6.64M	6.39M	6.98M
Retained Earnings	-55.89M	-76.24M	-120.65M	-194.01M	-383.48M	-991.93M	-1.4B	-2.11B	-2.4B	-1.57B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	5.08M	7.88M	14.11M	35.4M	53.04M	321.21M	465.41M	71.72M	72.07M	66.71M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.19M	11.15M	-43.84M	-61.59M	151.63M	-398.46M	-606.81M	-862.81M	-420.33M	-82.75M
Operating CF Margin %	-202.78%	72.04%	-100.36%	-250.63%	193.25%	-966.13%	-122.03%	-210.06%	-34.28%	-3.78%
Operating CF Growth %	-138.67%	173.36%	-493.33%	-40.47%	346.2%	-362.79%	-52.29%	-42.19%	51.28%	80.31%
Net Income	-17.06M	-22.52M	-27.51M	-93.63M	-198.89M	-477.62M	-348.75M	-720.34M	-425.05M	833.04M
Depreciation & Amortization	214.29K	351.27K	521.87K	563.94K	2.42M	3.92M	4.96M	104.34M	111.31M	17.53M
Stock-Based Compensation	2.48M	3M	5.12M	21.94M	44.24M	96.93M	179.37M	157.03M	232.97M	235.18M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-287	732	42.13K	-666.94K	-6.17M	6.68M	-101.44M	-27.91M	-30.67M	-843.89M
Working Capital Changes	-829K	30.32M	-22.02M	10.2M	310.03M	-28.38M	-340.95M	-375.93M	-308.89M	-324.6M
Change in Receivables	-712K	-646K	-146K	-50.33K	-25.71M	21.96M	-31.63M	-222.26M	-185.69M	-422.36M
Change in Inventory	0	0	0	0	0	-23.85M	-83.88M	-119.28M	-83.03M	-95.83M
Change in Payables	0	0	0	0	0	0	0	0	0	245.9M
Cash from Investing+	18.38M	-848K	-194.41M	-123.02M	-833.27M	344.69M	-347.07M	-461.18M	308.21M	-717.59M
Capital Expenditures	-300K	-883K	-414K	-712K	-1.8M	-1.07M	-3.62M	-837K	-812K	-1.8M
CapEx % of Revenue	4%	5.71%	0.95%	2.9%	2.29%	2.59%	0.73%	0.2%	0.07%	0.08%
Acquisitions	0	0	0	0	0	0	0	-2M	-13M	-7M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	18.68M	35K	-194M	-122.31M	-831.47M	345.76M	-115.21M	-89.84M	49.75M	45.15M
Cash from Financing+	260.2K	46.93M	366.35M	279.88M	733.73M	833M	1.12B	843.76M	1.34B	279.76M
Debt Issued (Net)	0	0	0	0	-1.51M	-2.55M	-3.85M	-4.17M	-3.8M	-7.64M
Equity Issued (Net)	260.2K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	0	-1.43M	-26.8M	-12.64M	-20.4M	22.37M	32.12M	86.97M	143.8M	-21.32M
Net Change in Cash	3.65M	57.2M	121.13M	103.15M	50.37M	844.64M	117.87M	-533.94M	1.25B	-548.91M
Free Cash Flow+	-15.5M	10.24M	-44.27M	-62.37M	104.89M	-403.6M	-728.25M	-966.63M	-464.14M	-151.05M
FCF Margin %	-206.85%	66.18%	-101.32%	-253.81%	133.69%	-978.6%	-146.45%	-235.33%	-37.85%	-6.9%
FCF Growth %	-135.15%	166.08%	-532.23%	-40.9%	268.18%	-484.77%	-80.44%	-32.73%	51.98%	67.46%
FCF per Share	-0.99	0.54	-1.80	-1.73	2.72	-8.89	-14.26	-17.78	-8.12	-2.32
FCF Conversion (FCF/Net Income)	0.91x	-0.50x	1.30x	0.81x	-0.84x	0.65x	1.49x	1.22x	1.42x	-0.10x
Interest Paid	0	0	0	0	0	0	0	0	0	378.4K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.94%	-41.86%	-14.02%	-14.81%	-20.18%	-42.63%	-19.37%	-26.54%	-8.54%	17.36%
Return on Invested Capital (ROIC)	-83.5%	-	-26.3%	-29.31%	-26.88%	-55.86%	-31.18%	-33.39%	-15.57%	-0.53%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	92.83%	90.39%	89.62%
Net Margin	-223.42%	-145.27%	-77.1%	-310.22%	-230.95%	-1475.29%	-81.97%	-172.76%	-24.06%	38.03%
Debt / Equity	-	-	-	-	0.01x	0.01x	0.00x	0.00x	0.00x	0.01x
Interest Coverage	-	-	-	-	-1430.88x	-1183.22x	-318.20x	-328.47x	-470.19x	-9.76x
FCF Conversion	0.91x	-0.50x	1.30x	0.81x	-0.84x	0.65x	1.49x	1.22x	1.42x	-0.10x
Revenue Growth	64.07%	106.51%	182.33%	-43.75%	219.3%	-47.44%	1105.72%	-17.4%	198.56%	78.6%

US Stock Screener

...

argenx SE (ARGX) 10-Year Financial Performance & Capital Metrics

ARGX •

HealthcareBiotechnologyImmunology and Inflammation Therapies

Revenue $2.19B +78.6%
EBITDA -$4M +98.7%
Net Income $833M +382.3%
EPS (Diluted) 12.78 +347.7%
Gross Margin 89.62% -0.9%
EBITDA Margin -0.19% +99.3%
Operating Margin -0.99% +97.1%
Net Margin 38.03% +258.1%
ROE 17.36% +303.3%
ROIC -0.53% +96.6%
Debt/Equity 0.01 +45.5%
Interest Coverage -9.76 +97.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 94.6%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 14.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y85.39%

5Y94.61%

3Y63.92%

TTM335.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM176.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM167.07%

ROCE

10Y Avg-20.84%

5Y Avg-16.64%

3Y Avg-13.15%

Latest-0.45%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.49M	15.47M	43.69M	24.57M	78.46M	41.24M	497.28M	410.75M	1.23B	2.19B
Revenue Growth %	64.07%	106.51%	182.33%	-43.75%	219.3%	-47.44%	1105.72%	-17.4%	198.56%	78.6%
Cost of Goods Sold+	0	0	0	0	0	0	0	29.43M	117.83M	227.29M
COGS % of Revenue	-	-	-	-	-	-	-	7.17%	9.61%	10.38%
Gross Profit+	7.49M	15.47M	43.69M	24.57M	78.46M	41.24M	497.28M	381.31M	1.11B	1.96B
Gross Margin %	100%	100%	100%	100%	100%	100%	100%	92.83%	90.39%	89.62%
Gross Profit Growth %	64.07%	106.51%	182.33%	-43.75%	219.3%	-47.44%	1105.72%	-23.32%	190.7%	77.08%
Operating Expenses+	24.55M	38M	71.2M	118.2M	277.35M	518.86M	846.02M	1.1B	1.53B	1.98B
OpEx % of Revenue	327.69%	245.55%	162.98%	481.02%	353.49%	1258.06%	170.13%	268.21%	125.05%	90.61%
Selling, General & Admin	5.38M	7.37M	14.93M	31.42M	72.15M	170.55M	305.52M	469.92M	709.54M	1.06B
SG&A % of Revenue	71.87%	47.65%	34.18%	127.88%	91.95%	413.53%	61.44%	114.41%	57.86%	48.18%
Research & Development	22.56M	33.19M	62.07M	95.64M	220.77M	370.49M	580.52M	663.37M	859.49M	983.42M
R&D % of Revenue	301.08%	214.48%	142.09%	389.21%	281.37%	898.31%	116.74%	161.5%	70.09%	44.9%
Other Operating Expenses	-3.39M	-2.56M	-5.81M	-8.86M	-15.56M	-22.18M	-40.02M	-31.63M	-35.5M	-54.16M
Operating Income+	-17.06M	-22.52M	-27.51M	-93.63M	-198.89M	-477.62M	-348.75M	-720.34M	-425.05M	-21.65M
Operating Margin %	-227.69%	-145.55%	-62.98%	-381.02%	-253.49%	-1158.06%	-70.13%	-175.37%	-34.66%	-0.99%
Operating Income Growth %	-30.6%	-32.01%	-22.15%	-240.31%	-112.43%	-140.14%	26.98%	-106.55%	40.99%	94.91%
EBITDA+	-16.85M	-22.17M	-26.99M	-93.06M	-196.47M	-473.7M	-342.88M	-616M	-313.57M	-4.13M
EBITDA Margin %	-224.83%	-143.28%	-61.78%	-378.72%	-250.4%	-1148.56%	-68.95%	-149.97%	-25.57%	-0.19%
EBITDA Growth %	-30.56%	-31.61%	-21.73%	-244.8%	-111.11%	-141.11%	27.62%	-79.65%	49.1%	98.68%
D&A (Non-Cash Add-back)	214.29K	351.27K	521.87K	563.94K	2.42M	3.92M	5.87M	104.34M	111.48M	17.53M
EBIT	-16.74M	-22.52M	-32.97M	-93.63M	-175.78M	-604.95M	-398.65M	-727.12M	-303.59M	87.64M
Net Interest Income+	83.09K	64.15K	197.95K	4.23M	8.67M	4.75M	2.39M	22.55M	92.06M	136.28M
Interest Income	83.09K	64.15K	197.95K	4.23M	8.8M	5.15M	3.48M	24.74M	92.96M	138.5M
Interest Expense	0	0	0	0	139K	403.66K	1.1M	2.19M	904K	2.22M
Other Income/Expense	320.34K	44.17K	-5.46M	18.3M	22.97M	-127.73M	-51M	-8.97M	120.55M	106.83M
Pretax Income+	-16.74M	-22.48M	-32.97M	-75.32M	-175.92M	-605.35M	-399.74M	-729.31M	-304.5M	85.18M
Pretax Margin %	-223.42%	-145.27%	-75.46%	-306.53%	-224.21%	-1467.77%	-80.39%	-177.56%	-24.83%	3.89%
Income Tax+	0	0	716.22K	908.26K	5.29M	3.1M	8.52M	-19.72M	-9.44M	-747.86M
Effective Tax Rate %	100%	100%	102.17%	101.21%	103.01%	100.51%	101.97%	97.3%	96.9%	977.98%
Net Income+	-16.74M	-22.48M	-33.68M	-76.23M	-181.21M	-608.46M	-407.63M	-709.59M	-295.05M	833.04M
Net Margin %	-223.42%	-145.27%	-77.1%	-310.22%	-230.95%	-1475.29%	-81.97%	-172.76%	-24.06%	38.03%
Net Income Growth %	-33.48%	-34.28%	-49.84%	-126.32%	-137.71%	-235.78%	33.01%	-74.08%	58.42%	382.34%
Net Income (Continuing)	-16.74M	-22.48M	-33.68M	-76.23M	-181.21M	-608.46M	-408.26M	-709.59M	-295.05M	833.04M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.06	-1.20	-1.37	-2.12	-4.69	-13.40	-7.99	-13.05	-5.16	12.78
EPS Growth %	-32.5%	-13.21%	-14.17%	-54.74%	-121.23%	-185.71%	40.37%	-63.33%	60.46%	347.67%
EPS (Basic)	-1.06	-1.19	-1.37	-2.12	-4.69	-13.40	-7.99	-13.05	-5.16	13.92
Diluted Shares Outstanding	15.73M	18.82M	24.61M	35.98M	38.62M	45.41M	51.08M	54.38M	57.17M	65.18M
Basic Shares Outstanding	15.73M	18.82M	24.61M	35.98M	38.62M	45.41M	51.08M	54.38M	57.17M	59.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.26M	107.06M	440.06M	654.82M	1.54B	2.06B	2.54B	2.77B	4.12B	4.88B
Cash & Short-Term Investments	46.28M	101.73M	431.62M	645.81M	1.5B	2B	2.34B	2.19B	3.18B	3.38B
Cash Only	38.83M	94.55M	228.98M	321.48M	372.16M	1.22B	1.33B	800.74M	2.05B	1.5B
Short-Term Investments	7.45M	7.18M	202.64M	324.33M	1.13B	779.65M	1B	1.39B	1.13B	1.88B
Accounts Receivable	719K	1.12M	845K	4.36M	36.17M	7.44M	38.22M	277.27M	499.27M	909.1M
Days Sales Outstanding	35.02	26.37	7.06	64.71	168.26	65.85	28.05	246.39	148.6	151.5
Inventory	0	0	0	0	0	25.2M	109.08M	228.35M	310.55M	407.23M
Days Inventory Outstanding	-	-	-	-	-	-	-	2.83K	961.94	653.97
Other Current Assets	637K	826.64K	3.85M	2.31M	0	0	0	0	0	0
Total Non-Current Assets+	2M	4.18M	4.92M	6.88M	67.54M	222.41M	307.3M	360.06M	418.72M	1.32B
Property, Plant & Equipment	272.23K	805.6K	811K	942.58K	9.18M	11.58M	15.84M	16.23M	22.68M	43.52M
Fixed Asset Turnover	27.52x	19.21x	53.87x	26.07x	8.55x	3.56x	31.39x	25.30x	54.08x	50.33x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7.65K	17.88K	15.6K	64.06K	45.12M	167.34M	171.68M	174.9M	125.23M	181.44M
Long-Term Investments	1.09K	1.05K	1.2K	1.14K	2.92M	6.31M	53.17M	40.48M	47.16M	49.7M
Other Non-Current Assets	1.71M	3.36M	4.1M	5.87M	10.33M	22.14M	34.42M	49.23M	126.45M	120.46M
Total Assets+	50.25M	111.24M	444.98M	661.7M	1.61B	2.28B	2.85B	3.13B	4.54B	6.2B
Asset Turnover	0.15x	0.14x	0.10x	0.04x	0.05x	0.02x	0.17x	0.13x	0.27x	0.35x
Asset Growth %	-14.12%	121.38%	300.01%	48.7%	143.35%	41.56%	25.04%	9.96%	44.93%	36.55%
Total Current Liabilities+	9.43M	34M	29.41M	45.82M	179.7M	328.49M	301.24M	302.28M	422.99M	669.92M
Accounts Payable	2.94M	4.63M	5.28M	6.87M	10.51M	206.32M	208.85M	188.72M	245.56M	342.23M
Days Payables Outstanding	-	-	-	-	-	-	-	2.34K	760.63	549.58
Short-Term Debt	0	0	0	0	2.22M	3.48M	3.51M	3.42M	4.65M	6.53M
Deferred Revenue (Current)	4.5M	37.27M	16.95M	23.21M	136.28M	46.33M	0	0	0	0
Other Current Liabilities	449.73K	329.08K	0	0	0	0	828K	22.62M	73.35M	156.95M
Current Ratio	5.12x	3.15x	14.96x	14.29x	8.58x	6.26x	8.44x	9.18x	9.75x	7.29x
Quick Ratio	5.12x	3.15x	14.96x	14.29x	8.58x	6.19x	8.08x	8.42x	9.01x	6.68x
Cash Conversion Cycle	-	-	-	-	-	-	-	737.91	349.92	255.89
Total Non-Current Liabilities+	0	10.59M	1.75M	8.01K	250.11M	276.86M	14.81M	18.29M	21.96M	34.32M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	5.1M	6.18M	7.96M	9.01M	15.35M	32.52M
Deferred Tax Liabilities	0	0	0	0	0	1.49M	6.44M	8.41M	5.16M	0
Other Non-Current Liabilities	0	10.59M	1.75M	8.01K	72K	156K	417K	870K	1.45M	1.8M
Total Liabilities	9.43M	44.59M	31.16M	45.83M	429.81M	605.36M	316.05M	320.56M	444.95M	704.24M
Total Debt+	0	0	0	0	7.32M	9.66M	11.46M	12.43M	20M	39.05M
Net Debt	-38.83M	-94.55M	-228.98M	-321.48M	-364.84M	-1.2B	-1.32B	-788.31M	-2.03B	-1.46B
Debt / Equity	-	-	-	-	0.01x	0.01x	0.00x	0.00x	0.00x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-1430.88x	-1183.22x	-318.20x	-328.47x	-470.19x	-9.76x
Total Equity+	40.76M	66.65M	413.81M	615.87M	1.18B	1.67B	2.53B	2.81B	4.1B	5.5B
Equity Growth %	-33.08%	63.54%	520.87%	48.83%	91.66%	41.82%	51.38%	11.03%	45.63%	34.19%
Book Value per Share	2.59	3.54	16.81	17.12	30.57	36.87	49.62	51.74	71.67	84.36
Total Shareholders' Equity	40.76M	66.65M	413.81M	615.87M	1.18B	1.67B	2.53B	2.81B	4.1B	5.5B
Common Stock	1.73M	2.12M	3.86M	4.12M	5.21M	5.74M	6.23M	6.64M	6.39M	6.98M
Retained Earnings	-55.89M	-76.24M	-120.65M	-194.01M	-383.48M	-991.93M	-1.4B	-2.11B	-2.4B	-1.57B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	5.08M	7.88M	14.11M	35.4M	53.04M	321.21M	465.41M	71.72M	72.07M	66.71M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.19M	11.15M	-43.84M	-61.59M	151.63M	-398.46M	-606.81M	-862.81M	-420.33M	-82.75M
Operating CF Margin %	-202.78%	72.04%	-100.36%	-250.63%	193.25%	-966.13%	-122.03%	-210.06%	-34.28%	-3.78%
Operating CF Growth %	-138.67%	173.36%	-493.33%	-40.47%	346.2%	-362.79%	-52.29%	-42.19%	51.28%	80.31%
Net Income	-17.06M	-22.52M	-27.51M	-93.63M	-198.89M	-477.62M	-348.75M	-720.34M	-425.05M	833.04M
Depreciation & Amortization	214.29K	351.27K	521.87K	563.94K	2.42M	3.92M	4.96M	104.34M	111.31M	17.53M
Stock-Based Compensation	2.48M	3M	5.12M	21.94M	44.24M	96.93M	179.37M	157.03M	232.97M	235.18M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-287	732	42.13K	-666.94K	-6.17M	6.68M	-101.44M	-27.91M	-30.67M	-843.89M
Working Capital Changes	-829K	30.32M	-22.02M	10.2M	310.03M	-28.38M	-340.95M	-375.93M	-308.89M	-324.6M
Change in Receivables	-712K	-646K	-146K	-50.33K	-25.71M	21.96M	-31.63M	-222.26M	-185.69M	-422.36M
Change in Inventory	0	0	0	0	0	-23.85M	-83.88M	-119.28M	-83.03M	-95.83M
Change in Payables	0	0	0	0	0	0	0	0	0	245.9M
Cash from Investing+	18.38M	-848K	-194.41M	-123.02M	-833.27M	344.69M	-347.07M	-461.18M	308.21M	-717.59M
Capital Expenditures	-300K	-883K	-414K	-712K	-1.8M	-1.07M	-3.62M	-837K	-812K	-1.8M
CapEx % of Revenue	4%	5.71%	0.95%	2.9%	2.29%	2.59%	0.73%	0.2%	0.07%	0.08%
Acquisitions	0	0	0	0	0	0	0	-2M	-13M	-7M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	18.68M	35K	-194M	-122.31M	-831.47M	345.76M	-115.21M	-89.84M	49.75M	45.15M
Cash from Financing+	260.2K	46.93M	366.35M	279.88M	733.73M	833M	1.12B	843.76M	1.34B	279.76M
Debt Issued (Net)	0	0	0	0	-1.51M	-2.55M	-3.85M	-4.17M	-3.8M	-7.64M
Equity Issued (Net)	260.2K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	0	-1.43M	-26.8M	-12.64M	-20.4M	22.37M	32.12M	86.97M	143.8M	-21.32M
Net Change in Cash	3.65M	57.2M	121.13M	103.15M	50.37M	844.64M	117.87M	-533.94M	1.25B	-548.91M
Free Cash Flow+	-15.5M	10.24M	-44.27M	-62.37M	104.89M	-403.6M	-728.25M	-966.63M	-464.14M	-151.05M
FCF Margin %	-206.85%	66.18%	-101.32%	-253.81%	133.69%	-978.6%	-146.45%	-235.33%	-37.85%	-6.9%
FCF Growth %	-135.15%	166.08%	-532.23%	-40.9%	268.18%	-484.77%	-80.44%	-32.73%	51.98%	67.46%
FCF per Share	-0.99	0.54	-1.80	-1.73	2.72	-8.89	-14.26	-17.78	-8.12	-2.32
FCF Conversion (FCF/Net Income)	0.91x	-0.50x	1.30x	0.81x	-0.84x	0.65x	1.49x	1.22x	1.42x	-0.10x
Interest Paid	0	0	0	0	0	0	0	0	0	378.4K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.94%	-41.86%	-14.02%	-14.81%	-20.18%	-42.63%	-19.37%	-26.54%	-8.54%	17.36%
Return on Invested Capital (ROIC)	-83.5%	-	-26.3%	-29.31%	-26.88%	-55.86%	-31.18%	-33.39%	-15.57%	-0.53%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	92.83%	90.39%	89.62%
Net Margin	-223.42%	-145.27%	-77.1%	-310.22%	-230.95%	-1475.29%	-81.97%	-172.76%	-24.06%	38.03%
Debt / Equity	-	-	-	-	0.01x	0.01x	0.00x	0.00x	0.00x	0.01x
Interest Coverage	-	-	-	-	-1430.88x	-1183.22x	-318.20x	-328.47x	-470.19x	-9.76x
FCF Conversion	0.91x	-0.50x	1.30x	0.81x	-0.84x	0.65x	1.49x	1.22x	1.42x	-0.10x
Revenue Growth	64.07%	106.51%	182.33%	-43.75%	219.3%	-47.44%	1105.72%	-17.4%	198.56%	78.6%

argenx SE (ARGX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ARGX vs Peers

vs CANF

vs AKTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

argenx SE (ARGX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ARGX vs Peers

vs CANF

vs AKTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios